Medicine
Zoladex 3.6 mg implant
Zoladex 3.6 mg implant is a prescription medicine containing Goserelin for subcutaneous use, marketed by TerSera Therapeutics, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at room temperature (do not exceed 25°C [77°F]).
Key facts
- Active ingredient (INN)
- Goserelin
- Brand
- Zoladex
- Strength
- 3.6 mg
- Dosage form
- Implant
- Route
- Subcutaneous
- Packs
- 1 pouch
- Marketing authorisation holder
- TerSera Therapeutics
- Manufacturer
- TerSera Therapeutics
- Origin register
- US FDA, United States
- Storage
- Store at room temperature (do not exceed 25°C [77°F]).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L02AE03 Goserelin
- HS code (indicative)
- 3004.39Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 31 March 2018
- Identifiers
- RxCUI 105641, 310592DailyMed set ID 294b168b-6e5f-4db9-bf70-d599271458b3NDC 70720-950Application NDA019726
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 pouch in 1 carton / 1 syringe in 1 pouch / 1 implant in 1 syringe | 70720-950-36 | TerSera Therapeutics | 31 March 2018 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 29 December 1989 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Goserelin
Clinical summary
Goserelin is a gonadotropin releasing hormone receptor agonist indicated for use in combination with flutamide for the management of locally confined carcinoma of the prostate, among other approved uses. It is available as implants for subcutaneous use. MedsAcross supplies Goserelin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about GoserelinFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- ZOLADEX prescribing information (TerSera Therapeutics) · U.S. National Library of Medicine, DailyMed
Need Zoladex 3.6 mg implant for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.